227 related articles for article (PubMed ID: 21463618)
1. A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance.
Zheng H; Li S; Ma L; Cheng L; Deng C; Chen Z; Xie C; Xiang M; Jiang W; Chen L
Eur J Pharmacol; 2011 Jun; 659(2-3):244-51. PubMed ID: 21463618
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of 5-benzylidenepyrimidine-2,4,6(1H,3H,5H)-trione derivatives for the treatment of obesity-related nonalcoholic fatty liver disease.
Ma L; Xie C; Ran Y; Liang X; Huang L; Pei H; Chen J; Liu J; Sang Y; Lai H; Peng A; Xiang M; Wei Y; Chen L
J Med Chem; 2012 Nov; 55(22):9958-72. PubMed ID: 23025244
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological activity of novel barbituric and thiobarbituric acid derivatives against non-alcoholic fatty liver disease.
Ma L; Li S; Zheng H; Chen J; Lin L; Ye X; Chen Z; Xu Q; Chen T; Yang J; Qiu N; Wang G; Peng A; Ding Y; Wei Y; Chen L
Eur J Med Chem; 2011 Jun; 46(6):2003-10. PubMed ID: 21429633
[TBL] [Abstract][Full Text] [Related]
4. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.
Stefanovic-Racic M; Perdomo G; Mantell BS; Sipula IJ; Brown NF; O'Doherty RM
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E969-77. PubMed ID: 18349115
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of non-alcoholic fatty liver disease.
Ma L; Chen J; Liang X; Xie C; Deng C; Huang L; Peng A; Wei Y; Chen L
Arch Pharm (Weinheim); 2012 Jul; 345(7):517-24. PubMed ID: 22532295
[TBL] [Abstract][Full Text] [Related]
6. Daidzein supplementation prevents non-alcoholic fatty liver disease through alternation of hepatic gene expression profiles and adipocyte metabolism.
Kim MH; Park JS; Jung JW; Byun KW; Kang KS; Lee YS
Int J Obes (Lond); 2011 Aug; 35(8):1019-30. PubMed ID: 21157426
[TBL] [Abstract][Full Text] [Related]
7. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
Zaitone S; Hassan N; El-Orabi N; El-Awady el-S
Eur J Pharmacol; 2011 Jul; 662(1-3):70-7. PubMed ID: 21549113
[TBL] [Abstract][Full Text] [Related]
8. Protective effects of fractional extracts from Panellus serotinus on non-alcoholic fatty liver disease in obese, diabetic db/db mice.
Inafuku M; Nagao K; Nomura S; Shirouchi B; Inoue N; Nagamori N; Nakayama H; Toda T; Yanagita T
Br J Nutr; 2012 Mar; 107(5):639-46. PubMed ID: 21787451
[TBL] [Abstract][Full Text] [Related]
9. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
10. Berberine reducing insulin resistance by up-regulating IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD) rat liver.
Xing LJ; Zhang L; Liu T; Hua YQ; Zheng PY; Ji G
Eur J Pharmacol; 2011 Oct; 668(3):467-71. PubMed ID: 21839075
[TBL] [Abstract][Full Text] [Related]
11. Dietary folic acid activates AMPK and improves insulin resistance and hepatic inflammation in dietary rodent models of the metabolic syndrome.
Buettner R; Bettermann I; Hechtl C; Gäbele E; Hellerbrand C; Schölmerich J; Bollheimer LC
Horm Metab Res; 2010 Oct; 42(11):769-74. PubMed ID: 20803414
[TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis.
Svegliati-Baroni G; Saccomanno S; Rychlicki C; Agostinelli L; De Minicis S; Candelaresi C; Faraci G; Pacetti D; Vivarelli M; Nicolini D; Garelli P; Casini A; Manco M; Mingrone G; Risaliti A; Frega GN; Benedetti A; Gastaldelli A
Liver Int; 2011 Oct; 31(9):1285-97. PubMed ID: 21745271
[TBL] [Abstract][Full Text] [Related]
13. A selective peroxisome proliferator-activated receptor gamma modulator with distinct fat cell regulation properties.
Fujimura T; Kimura C; Oe T; Takata Y; Sakuma H; Aramori I; Mutoh S
J Pharmacol Exp Ther; 2006 Aug; 318(2):863-71. PubMed ID: 16682454
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activator inhibitor-1 modulates adipocyte differentiation.
Liang X; Kanjanabuch T; Mao SL; Hao CM; Tang YW; Declerck PJ; Hasty AH; Wasserman DH; Fogo AB; Ma LJ
Am J Physiol Endocrinol Metab; 2006 Jan; 290(1):E103-E113. PubMed ID: 16144810
[TBL] [Abstract][Full Text] [Related]
15. Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.
Choi KC; Ryu OH; Lee KW; Kim HY; Seo JA; Kim SG; Kim NH; Choi DS; Baik SH; Choi KM
Biochem Biophys Res Commun; 2005 Oct; 336(3):747-53. PubMed ID: 16157299
[TBL] [Abstract][Full Text] [Related]
16. Amelioration of insulin resistance by scopoletin in high-glucose-induced, insulin-resistant HepG2 cells.
Zhang WY; Lee JJ; Kim Y; Kim IS; Park JS; Myung CS
Horm Metab Res; 2010 Dec; 42(13):930-5. PubMed ID: 20886413
[TBL] [Abstract][Full Text] [Related]
17. Effect of PPAR-delta agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes.
Choi KC; Lee SY; Yoo HJ; Ryu OH; Lee KW; Kim SM; Baik SH; Choi KM
Biochem Biophys Res Commun; 2007 May; 357(1):62-7. PubMed ID: 17418807
[TBL] [Abstract][Full Text] [Related]
18. Prevention of free fatty acid-induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction.
Jun DW; Cho WK; Jun JH; Kwon HJ; Jang KS; Kim HJ; Jeon HJ; Lee KN; Lee HL; Lee OY; Yoon BC; Choi HS; Hahm JS; Lee MH
Liver Int; 2011 Oct; 31(9):1315-24. PubMed ID: 22093454
[TBL] [Abstract][Full Text] [Related]
19. Flaxseed lignan attenuates high-fat diet-induced fat accumulation and induces adiponectin expression in mice.
Fukumitsu S; Aida K; Ueno N; Ozawa S; Takahashi Y; Kobori M
Br J Nutr; 2008 Sep; 100(3):669-76. PubMed ID: 18252024
[TBL] [Abstract][Full Text] [Related]
20. Rosiglitazone inhibits expression and secretion of PEDF in adipose tissue and liver of male SD rats via a PPAR-γ independent mechanism.
Yang S; Luo T; Zhou H; Lv Q; Liu L; Zhang W; Gao R; Chen S; Xia W; Luo M; Cheng Q; Li Q
Endocrinology; 2014 Mar; 155(3):941-50. PubMed ID: 24424059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
